Bioage Labs Inc (BIOA)

개요 뉴스 가격 이력 토론 예측

Relative Volume:

Bioage Labs Inc Stock (BIOA) Company Profile

Bioage Labs Inc

Healthcare (1119)

510-806-1445

5885 HOLLIS STREET, EMERYVILLE

최신 SEC 제출 서류

BIOA's Discussions on Twitter

BIOA을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
BIOA Bioage Labs Inc	18.66	721.40M	0	0	0	0.00
ZTS Zoetis Inc	125.08	55.12B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	16.01	50.80B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	10.27	45.60B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	31.84	36.04B	16.88B	666.71M	251.19M	0.6132
UTHR United Therapeutics Corp	468.12	20.23B	3.08B	1.24B	1.07B	25.61

Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-12-05	업그레이드	Morgan Stanley	Underweight → Equal-Weight
2025-10-22	업그레이드	Citigroup	Neutral → Buy
2025-02-28	개시	William Blair	Mkt Perform
2024-12-10	다운그레이드	Morgan Stanley	Overweight → Underweight
2024-12-09	다운그레이드	Citigroup	Buy → Neutral
2024-12-09	다운그레이드	Jefferies	Buy → Hold
2024-10-21	개시	Citigroup	Buy
2024-10-21	개시	Jefferies	Buy
2024-10-21	개시	Morgan Stanley	Overweight

Bioage Labs Inc 주식(BIOA)의 최신 뉴스

Bioage Labs Inc (BIOA) 재무 분석

Bioage Labs Inc (BIOA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

Bioage Labs Inc 주식 (BIOA) 내부자 거래

내부자 거래	관계	날짜	거래	비용	#주식	가치 ($)	#주식 총계
GOLDSTEIN DOV A MD	Chief Financial Officer	Jan 13 '26	Option Exercise	8.39	27,000	226,530	49,408
GOLDSTEIN DOV A MD	Chief Financial Officer	Jan 13 '26	Sale	19.70	27,000	531,828	22,408
Fortney Kristen	Chief Executive Officer	Jan 13 '26	Sale	18.12	233,107	4,223,036	976,949

Bioage Labs Inc (BIOA)

Bioage Labs Inc Stock (BIOA) Company Profile

BIOA을(를) 다른 주식과 비교

Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades

Bioage Labs Inc 주식(BIOA)의 최신 뉴스

BioAge Labs prices upsized public offering at $19.50 per share By Investing.com - Investing.com Nigeria

Fund Flows: Is BioAge Labs Inc in accumulation or distribution phase2025 Market WrapUp & Reliable Price Action Trade Plans - baoquankhu1.vn

BioAge Labs prices upsized public offering at $19.50 per share - Investing.com

Metabolic disease biotech BioAge raises $115M in stock sale - Stock Titan

BioAge Announces Pricing of Upsized $115.0 Million Public Offering - GlobeNewswire

Dow Update: Will SPDR Gold Trust benefit from rate cutsTrade Ideas & Pattern Based Trade Signal System - baoquankhu1.vn

BioAge Labs (NASDAQ:BIOA) Shares Gap DownTime to Sell? - MarketBeat

Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga

BioAge Announces Proposed $75 Mln Public Offering; Expands BGE-102 Development Into Ophthalmology - Nasdaq

BioAge Labs announces $75 million public stock offering By Investing.com - Investing.com Nigeria

BioAge expands BGE-102 program to diabetic macular edema By Investing.com - Investing.com India

BioAge Labs: Early-Stage Promise for BGE-102 Balanced by Long Timelines and Clinical Risk, Justifying Hold Rating - TipRanks

BioAge stock falls after announcing $75 million public offering By Investing.com - Investing.com UK

BioAge Labs announces $75 million public stock offering - Investing.com

BioAge Announces Proposed Public Offering - manilatimes.net

BioAge Announces Proposed Public Offering - Benzinga

BioAge Labs: Early-Stage NLRP3 Opportunity in Ophthalmology and Cardiometabolic Disease Warrants Neutral ‘Hold’ Amid Long Clinical Timelines - TipRanks

BioAge expanding indication for NLRP3 inhibitor BGE-102 into DME - The Pharma Letter

BioAge expands BGE-102 program to diabetic macular edema - Investing.com

BioAge Labs advances BGE-102 into ophthalmology clinical trials - TipRanks

BioAge Labs, Inc. Expands Indication for BGE-102 to Diabetic Macular Edema - TradingView — Track All Markets

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 - The Manila Times

Pill for diabetic eye swelling: BioAge tests oral alternative to eye injections - Stock Titan

BioAge Labs extends rally after updating early-stage trial data for lead drug - MSN

BioAge Labs (NASDAQ:BIOA) Stock Rating Upgraded by Wall Street Zen - MarketBeat

BioAge Labs: Why Getting Into The Brain Might Be A Headache For Investors (NASDAQ:BIOA) - Seeking Alpha

The JPM Effect In Short Supply But BioAge And Bayer Gain - Citeline News & Insights

BioAge Labs (NASDAQ:BIOA) Shares Down 6.1% on Insider Selling - MarketBeat

Bioage Labs Inc (BIOA) Stock Price Down 5.15% on Jan 16 - GuruFocus

Insider Selling: CEO Kristen Fortney Sells Shares of Bioage Labs Inc (BIOA) - GuruFocus

Insider Selling: BioAge Labs (NASDAQ:BIOA) CEO Sells 233,107 Shares of Stock - MarketBeat

Dov Md Goldstein Sells 27,000 Shares of BioAge Labs (NASDAQ:BIOA) Stock - MarketBeat

Bioage Labs Insider Sold Shares Worth $4,223,036, According to a Recent SEC Filing - marketscreener.com

Bioage Labs Insider Sold Shares Worth $531,828, According to a Recent SEC Filing - marketscreener.com

BioAge Labs (NASDAQ:BIOA) Shares Up 7.1%Time to Buy? - MarketBeat

BioAge reports 86% reduction in inflammation markers with BGE-102 By Investing.com - Investing.com India

BioAge Labs (NASDAQ:BIOA) Reaches New 1-Year HighShould You Buy? - MarketBeat

BioAge stock soars 21% on positive data for inflammation drug By Investing.com - Investing.com South Africa

BioAge stock soars 21% on positive data for inflammation drug - Investing.com

BioAge Labs advances BGE-102 with strong Phase 1 data - TipRanks

BioAge Labs, Inc. Announces Positive Interim Phase 1 Data for BGE-102 - TradingView — Track All Markets

BioAge announces additional positive interim phase 1 data for BGE-102, a novel brain-penetrant NLRP3 inhibitor, demonstrating potential for best-in-class hsCRP reduction in participants with elevated cardiovascular risk - marketscreener.com

Experimental pill sharply cuts heart inflammation in 2 weeks - Stock Titan

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with... - markets.businessinsider.com

Institutional investors are BioAge Labs, Inc.'s (NASDAQ:BIOA) biggest bettors and were rewarded after last week's US$51m market cap gain - simplywall.st

Weekly Earnings: Will The Chemours Company 2CU stock benefit from sector leadershipWeekly Trading Summary & Safe Capital Growth Plans - Bộ Nội Vụ

Is BioAge Labs Inc. stock dividend yield sustainableJuly 2025 Reactions & Fast Exit Strategy with Risk Control - ulpravda.ru

Can BioAge Labs Inc. stock deliver sustainable ROERelative Strength Index (RSI) & Individual Stock Tracking Service - bollywoodhelpline.com

Aug Ideas: Will BioAge Labs Inc. stock maintain growth storyRate Hike & Target Return Focused Stock Picks - Улправда

How analysts rate BioAge Labs Inc. stock todayJuly 2025 News Drivers & Reliable Momentum Entry Alerts - Улправда

Is BioAge Labs Inc. (Y7G) stock included in top ETFs2025 Pullback Review & Low Drawdown Momentum Trade Ideas - ulpravda.ru

Bioage Labs Inc (BIOA) 재무 분석

매출

순이익

현금흐름

주당 순 이익

Bioage Labs Inc 주식 (BIOA) 내부자 거래

BIOA과 유사한 종목